Filtered By:
Infectious Disease: Endemics
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 382 results found since Jan 2013.
Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
Dengue is the most common arboviral disease caused by one of four distinct but closely related dengue viruses (DENV) and places significant economic and public health burdens in the endemic areas. A dengue vaccine will be important in advancing disease control. However, the effort has been challenged by the requirement to induce effective protection against all four DENV serotypes and the potential adverse effect due to the phenomenon that partial immunity to DENV may worsen the symptoms upon subsequent heterotypic infection. Currently, the most advanced dengue vaccines are all tetravalent and based on recombinant live att...
Source: Frontiers in Immunology - February 24, 2022 Category: Allergy & Immunology Source Type: research
UCLA-led team gets $8.4 million NIH grant to probe mysteries of Valley Fever
Why do some people infected with Valley Fever develop a potentially fatal form of the disease that ravages their body while most experience only mild symptoms or none at all?A team led by UCLA ’s Dr. Manish Butte has been awarded an $8.4 million grant from the National Institute of Allergy and Infectious Diseases to study this and other questions related to genetic risk factors and immune responses to the disease, which occurs when people breathe in microscopic spores of the fungusCoccidioides that are present in soil.First identified in Argentina in the late 1800s, Valley Fever today is seen in a geographic swath that s...
Source: UCLA Newsroom: Health Sciences - February 15, 2022 Category: Universities & Medical Training Source Type: news
Ebola vaccine being used in Congo produces lasting antibody response, study finds
FINDINGSA new study by UCLA researchers and colleagues demonstrates that the Ebola vaccine known as rVSV ΔG-ZEBOV-GP results in a robust and enduring antibody response among vaccinated individuals in areas of the Democratic Republic of Congo that are experiencing outbreaks of the disease. Among the more than 600 study participants, 95.6% demonstrated antibody persistence six months after they received the vaccine.The study is the first published research examining post –Ebola-vaccination antibody response in the DRC, a nation of nearly 90 million. While long-term analyses of the study cohort continue, the findings will ...
Source: UCLA Newsroom: Health Sciences - February 8, 2022 Category: Universities & Medical Training Source Type: news
A point-of-care cassette test for detection of Strongyloides stercoralis
Acta Trop. 2021 Nov 19:106251. doi: 10.1016/j.actatropica.2021.106251. Online ahead of print.ABSTRACTStrongyloides stercoralis is a parasite that causes strongyloidiasis worldwide. It may lead to a life-long infection in immunocompetent people and hyperinfection in immunosuppressed patients. A point-of-care (POC) rapid test is helpful for patient diagnosis in resource-limited settings and as a detection tool in elimination/control programs. Previously, we reported a rapid IgG4 dipstick test (SsRapid®) for Strongyloides suitable for a laboratory setting. A POC cassette format of the test, which is field-applicable, has sin...
Source: Acta Tropica - November 22, 2021 Category: Infectious Diseases Authors: R Noordin E Osman N Kalantari N S Anuar T Gorgani-Firouzjaee P Sithithaworn N M Juri A Rahumatullah Source Type: research
M292 a case of rhinosporidiosis of the nasal cavity
Rhinosporidiosis is a rare chronic granulomatous disease caused by Rhinosporidium seeberi that is characterized by vascular polyps on mucosal surfaces. The disease is endemic in south India, Sri Lanka, and parts of Africa. A few isolated cases have been reported from the United States
Source: Annals of Allergy, Asthma and Immunology - November 1, 2021 Category: Allergy & Immunology Authors: J.H. Jung Source Type: research
Study Shows Vaccine Protects Dogs Against Valley Fever
This study was supported in part by the National Institutes of Allergy and Infectious Disease, a division of the National Institutes of Health (R01AI132140), and Anivive Lifesciences, Inc.A version of this article originally appeared on the University of Arizona Health Sciences website:https://healthsciences.arizona.edu/newsroom/news-releases/2021/study-shows-vaccine-protects-dogs-against-valley-fever.
Source: The University of Arizona: Health - October 26, 2021 Category: Universities & Medical Training Authors: mittank Source Type: research
Safety and side effect profile of Pfizer-BioNTech COVID-19 vaccination among healthcare workers: A tertiary hospital experience in Singapore
CONCLUSION: The side effects experienced after Pfizer-BioNTech COVID-19 vaccines are generally self-limiting and mild, with no anaphylaxis reported.PMID:34625758 | DOI:10.47102/annals-acadmedsg.2021160
Source: Ann Acad Med Singapo... - October 9, 2021 Category: General Medicine Authors: See Ming Lim Hwang Ching Chan Amelia Santosa Swee Chye Quek Eugene Hern Choon Liu Jyoti Somani Source Type: research
